SCHEMBL26089258

SCHEMBL26089258

Cc1nc(CC(=O)O)ccc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B1 P15121 1/20 0.41
KDM4E B2RXH2 2/20 0.40
ALDH1A1 P00352 2/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.39
DGAT1 O75907 5/20 0.37
CA2 P00918 1/20 0.37
GABRA5 P31644 1/20 0.37
GABRB2 P47870 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MCL1 Q07820 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
CLIC1 O00299 1/20 0.36
CXCL8 P10145 1/20 0.36
CLCN2 P51788 1/20 0.36
SOAT1 P35610 3/20 0.36
NPC1 O15118 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28545685 0.84 HTT (0.42) ALDH1A1POLBL3MBTL1DGAT1CA2
SCHEMBL27951352 0.79 ALDH1A1 (0.41) AKR1B1KDM4EALDH1A1POLBTDP1
SCHEMBL25301682 0.78 RAB9A (0.42) KDM4EALDH1A1POLBTDP1L3MBTL1
SCHEMBL30484050 0.78 RAB9A (0.42) KDM4EALDH1A1POLBTDP1L3MBTL1
SCHEMBL11786551 0.75 THRB (0.40) AKR1B1L3MBTL1MCL1GAA
SCHEMBL10272814 0.74 NOS3 (0.33) KDM4EALDH1A1HSD17B10SMN1; SMN2MAPT
SCHEMBL4549698 0.74 SMN1; SMN2 (0.40) KDM4EALDH1A1POLBTDP1L3MBTL1
SCHEMBL16049888 0.72 NOTUM (0.35)
SCHEMBL5363365 0.72 GABRA5 (0.46) AKR1B1KDM4EALDH1A1POLBTDP1
SCHEMBL12436364 0.70 KDM4E (0.42) AKR1B1KDM4EALDH1A1PTGDR2CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240294495-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS AG (CH) 2024-09-05 US disclosed
WO-2023069731-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF MONTE ROSA THERAPEUTICS, INC. (US) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240294495-A1 COMPOUNDS THAT MEDIATE PROTEIN DEGRADATION AND METHODS OF USE THEREOF CRBN, GSPT1, GSPT2 AKR1B1 3665/4885KDM4E 3525/4885ALDH1A1 4056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.